Back to Agenda
Value Demonstration Planning for Pharmaceutical Companies to Support Pricing and Reimbursement - Opportunities and Challenges
Session Chair(s)
Claudine Sapède, PharmD
Director, Global HTA Policy
NOVARTIS INTERNATIONAL, Switzerland
Value demonstration is critical in receiving access for patients for new medicines today and in the future. In an environment where new possibilities open to get regulatory approval quicker than usual, new challenges appear for decreasing uncertainties in value demonstration for payors and HTA bodies. This session will present new findings and results and explore new possibilities.
Learning Objective : 1. Learn about key challenges and benefits of Adaptive Pathway pilots based on 2 pilots in a global Company; how we tackled the need for cross-functional collaboration to achieve a common understanding . 2. Hear about the difficulties of making changes in the overall evidence plan and requesting upfront investment whilst achieving an integrated approach taking account of post-approval activities.
Speaker(s)
Findings from a Fast-Track Drug
Chris Hoyle
AstraZeneca, United Kingdom
Director Payer & HTA Policy
Conclusions from an Adaptive Pathways Project
Regina Seidel, RPh
Bayer AG, Germany
Using Real World Evidence to Demonstrate Value
Adrian Cassidy, PhD, MSc
Novartis, Switzerland
Head Global Evidence Generation
Have an account?